Cancer UrologyPub Date : 2023-02-28DOI: 10.17650/1726-9776-2022-18-4-15-24
A. Kuzevanova, O. Khalmurzaev, A. A. Borunova, N. Apanovich, T. Zabotina, A. A. Alimov, V. Matveev, A. Karpukhin
{"title":"Study of the action of peripheral blood T-lymphocytes on renal cell carcinoma cells in model systems","authors":"A. Kuzevanova, O. Khalmurzaev, A. A. Borunova, N. Apanovich, T. Zabotina, A. A. Alimov, V. Matveev, A. Karpukhin","doi":"10.17650/1726-9776-2022-18-4-15-24","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-4-15-24","url":null,"abstract":"Background. The introduction of immunotherapy based on immune checkpoint inhibitors has significantly improve the effectiveness of kidney cancer treatment. Nevertheless, not all patients respond to such treatment and there are no reliable predictive markers. Therefore, the development of a model system for assessing the cellular immune response to a tumor seems to be an urgent task.Aim. Development of a model to assess the T-cell immune response was the focus of this study.Materials and methods. Primary tumor cell culture and peripheral blood T-cell fraction were obtained under standard sterile conditions. T-cell activation were perform via anti-CD3 and anti-CD28 antibodies. The cell index was assessed using the RTCA xCELLigence biosensor technology (ACEA Biosciences, USA).Results. Tumor and T-cells from the same patient were cultured together to assess the growth rate of the tumor cell population. Measurements were taken at 30-minute intervals. The duration of observation was 24 hours. It has been shown that non-activated T-cells do not affect the proliferative properties of cultured cancer cells. On the contrary, activated T-cells suppressed the proliferative properties of cancer cells, which was associated with an increase in the proportion of Т-cells carrying the HLA-DR receptor (CD3+HLA–DR+) because of activation. Tumor-specific T-cell activity can lead to three consequences: lack of effect, partial suppression of proliferative properties, and complete death of tumor cells. In the latter case, the absence of such cells was determined by flow cytometry.Conclusion. The developed approach makes it possible to evaluate the cytotoxic properties of T cells in relation to tumor cells in a particular patient. The advantage of this method is that the measurement can be carried out in the presence of immune checkpoint inhibitors. The proposed method may be useful for evaluating the treatment regimen within the framework of personalized therapy.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126047663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-123-127
A. Martov, D. V. Ergakov, A. Andronov
{"title":"Upper tract urothelial carcinoma: can the tumor be removed en bloc?","authors":"A. Martov, D. V. Ergakov, A. Andronov","doi":"10.17650/1726-9776-2022-18-3-123-127","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-123-127","url":null,"abstract":"Diagnosis and treatment of upper tract urothelial carcinoma (UTUC) remain important problems of clinical urology. UTUC en bloc i.e. in one-piece removal during organ-sparing surgery is still hardly possible. The most typical endourological operations are either electrosurgery, holmium or thulium YAG laser tumor vaporization.We present a clinical case of ureteroscopic en bloc UTUC removal using a new super pulse thulium fiber laser (SPTFL, FiberLase U3). Recent innovations and trends in this field are also discussed. The technical steps of en bloc ureteroscopic tumor removal allowing for diagnosis verification, identification of pT stage and surgical margin are described. The further innovations in laser UTUC removal include modulation of laser pulse length and development of the correlation between preoperative tumor characteristics and possibility of en bloc removal.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"158 3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128848225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-135-144
L. Zhuikova, O. Ananina, L. V. Pikalova, G. A. Kononova
{"title":"The impact of the COVID-19 pandemic on cancer incidence and cancer care in patients with prostate cancer in the Siberian Federal District","authors":"L. Zhuikova, O. Ananina, L. V. Pikalova, G. A. Kononova","doi":"10.17650/1726-9776-2022-18-3-135-144","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-135-144","url":null,"abstract":"Background. Prostate cancer incidence rates continue to increase every year, therefore, the study of the quality indicators for cancer care, especially during a pandemic, is of great importance.Aim. To analyze prostate cancer incidence rates and quality indicators of cancer care in the Siberian Federal District.Materials and methods. For the calculation of cancer incidence rates, population-bases cancer registry data were used. Quality indicators were calculated according to the methodological recommendations of P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center.Results. The implementation of restrictive measures and the suspension of cancer screening programs in 2020 negatively affected the cancer care. The prostate cancer incidence rate decreased from 52.8 per 100 000 population in 2019 to 43.1 per 100 000 population in 2020, especially in the territories of the Republic of Tyva and the Omsk Region. Morphological verification in 2020 decreased compared to 2019 (97.0 % versus 97.8 %), with the exception of the Krasnoyarsk Territory and the Republic of Altai. Early prostate cancer detection increased from 62.9 to 64.0 %, and cancer detection at late stages decreased from 36.3 to 35.0 %. One-year mortality in the region decreased from 8.0 % (2019) to 7,3 % (2020), however, it increased significantly in the Republic of Tyva (from 3.2 to 40.0 %) and the Altai Republic (from 3.7 to 10.7 %). The number of patients who have been followed-up for 5 years or more increased from 40.7 to 42.3 %, except for Republic of Altai (from 32.8 to 25.0 %).Conclusion. Delay in the diagnosis of prostate cancer is associated with advanced stage, poor survival and high cost treatment.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131222593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-107-115
S. Popov, R. Guseynov, O. Skryabin, V. V. Perepelitsa, A. V. Davydov, R. S. Barkhitdinov, A. Katunin, M. M. Mirzabekov
{"title":"Molecular-genetic and cytogenetic characteristics of sporadic kidney cancer: literature review","authors":"S. Popov, R. Guseynov, O. Skryabin, V. V. Perepelitsa, A. V. Davydov, R. S. Barkhitdinov, A. Katunin, M. M. Mirzabekov","doi":"10.17650/1726-9776-2022-18-3-107-115","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-107-115","url":null,"abstract":"To compile this literature review, we studied at least 100 publications devoted to the genetic basis of clear cell, papillary, and chromophobic sporadic kidney cancer pathogenesis. Each of them considered the role of somatic gene and chromosomal mutations in the initiation, promotion, and tumor progression of sporadic renal cell carcinoma, emphasized the importance of determining the mutagenic profile of renal cell carcinoma for the future fate of patients.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114364469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-99-106
V. Kapinus, O. Karyakin, E. V. Yaroslavtseva-Isaeva, O. E. Popovkina, S. A. Ivanov, А. Kaprin
{"title":"Experience of using photodynamic therapy in early stages of penile cancer","authors":"V. Kapinus, O. Karyakin, E. V. Yaroslavtseva-Isaeva, O. E. Popovkina, S. A. Ivanov, А. Kaprin","doi":"10.17650/1726-9776-2022-18-3-99-106","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-99-106","url":null,"abstract":"Background. Penile cancer is a rare oncological pathology. Due to the intimate nature of the affected area and high significance of the organ for psycho-emotional state of the patient, at the early stages of the disease organ-sparing operations are preferred allowing to minimize the effect on patient’s quality of life without affecting oncological results.Aim. To evaluate the effectiveness of treatment of early stages penile cancer using photodynamic therapy (PDT) with chlorin E6 derivatives.Materials and methods. Between 2017 and 2021, PDT with chlorin E6 derivatives to treat early-stage penile cancer was performed in 15 patients between the ages of 29 and 84 years (mean age 56.4 years). Tumor stage was Tin situ–1bN0M0. PDT was performed with preliminary administration of Photolon and Photoran photosensitizers. Laser exposure on the tumor lesions was performed 3 hours after photosensitizer administration using laser device Latus-2 (662 nm), light dose 200–300 J/cm2, power density 0.21–0.41 mW/cm2.Results. After 1 PDT session, full regression was observed in 11 (73.3 %) patients, partial regression in 4 (26.7 %) patients who underwent 2nd session 2 months later with full effect. Therefore, in all patients full regression of the tumors was achieved. Follow-up duration was 6–56 months. Recurrence was diagnosed in 1 (6.7 %) patient 36 months after PDT, 14 (93.3 %) patients are under observation without signs of local recurrence, among them for more than 4 years – 3 men, more than 3 years – 1, more than 2 years – 3, more than 1 year – 4 and more than 6 months – 3. During the follow-up, no regional or distant metastases were observed in any of the patients.Conclusion. PDT with chlorin E6 derivatives is an effective organ-sparing treatment method for early-stage penile cancer with satisfactory oncological results without negative effect on patients’ quality of life. In 93.3 % of patients, local recurrence of the disease was not observed; during follow-up no distant metastases were diagnosed. It is necessary to point out satisfactory cosmetic results of the treatment: in all patients, elastic non-deforming scars were formed with full preservation of anatomical structures of the penis, no erectile dysfunction or disruption of urination were observed after PDT.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122703913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-128-134
A. A. Kеln, G. S. Petrosyan, A. Kupchin, A. Lykov, A. V. Lebedev, L. V. Volynkina
{"title":"The probability of developing a tumor in the small intestine neocyst","authors":"A. A. Kеln, G. S. Petrosyan, A. Kupchin, A. Lykov, A. V. Lebedev, L. V. Volynkina","doi":"10.17650/1726-9776-2022-18-3-128-134","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-128-134","url":null,"abstract":"In clinical practice and scientific literature, there is very little data on the occurrence of tumors in the urinary intestinal reservoirs in patients after radical cystectomy with cystoplasty. A characteristic feature of such tumors is a long latent period before the formation of a relapse from 4 to 32 years.The article describes a clinical case of a 1951 patient with a tumor of a small intestinal neocyst. From the patient’s history, there is a long-term hematuria (for 2 years) after radical cystectomy with ileocystoplasty. The intensity of hematuria increased to the formation of profuse with the development of severe anemia. During the examination according to magnetic resonance imaging, computed tomography, ultrasound and invasive diagnostic examinations, no tumor was detected. The patient underwent a diagnostic laparotomy, a tumor was found in the area of ureteral-reservoir anastomosis of the small intestine neocyst. Resection of the small intestine reservoir and ureteral transplantation was performed. The morphological picture of the removed tumor is urothelial cancer of moderate differentiation.Secondary tumors of the small intestinal urinary reservoirs are rare and have the structure of adenocarcinoma. The mechanisms of their occurrence have not been fully studied at the moment. Dynamic monitoring of patients after radical cystectomy and ileocystoplasty should be carried out in a specialized center.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129287614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-10DOI: 10.17650/1726-9776-2022-18-3-116-122
E. Sirota, Y. Alyaev, L. M. Rapоport, D. Tsarichenko, I. Kasiteridi, O. V. Arutyunyan
{"title":"Laparoscopic resection of localized tumors of horseshoe kidney parenchyma using 3D printing: clinical observation","authors":"E. Sirota, Y. Alyaev, L. M. Rapоport, D. Tsarichenko, I. Kasiteridi, O. V. Arutyunyan","doi":"10.17650/1726-9776-2022-18-3-116-122","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-116-122","url":null,"abstract":"The use of 3D-computer technologies (3D-modeling, 3D-printing) in the surgical treatment of patients with kidney abnormalities contributes to a better understanding of anatomy at the preoperative planning stage and improves intraoperative navigation. We present a clinical observation using 3D-printing during performing organ-preserving laparoscopic surgery in a patient with localized formations of the horseshoe kidney parenchyma.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131846597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-09DOI: 10.17650/1726-9776-2022-18-3-67-75
K. Nyushko, V. M. Perepukhov, B. Alekseev
{"title":"Nomograms for predicting local recurrence in prostate cancer patients with a positive resection margin","authors":"K. Nyushko, V. M. Perepukhov, B. Alekseev","doi":"10.17650/1726-9776-2022-18-3-67-75","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-67-75","url":null,"abstract":"Background. Prostate cancer patients with a positive resection margin after radical prostatectomy are at risk of developing local recurrence. This risk should be carefully estimated in order to choose an optimal management strategy.Aim. To develop a nomogram to predict the risk of local recurrence in patients with a positive resection margin using the data on patients who have undergone surgery.Materials and methods. Routine pathomorphological examination of surgical specimens from 2255 patients with clinically significant local and locally advanced prostate cancer revealed 364 cases of positive resection margin. Statistical analysis allowed us to identify the most significant prognostic factors. Using selected preoperative factors and a mathematical model, we created a nomogram to predict local recurrence in patients with a positive resection margin.Results. Our nomogram had an accuracy of 93% (area under the ROC curve (AUC) 0.9392; p <0.005), sensitivity of 0.99438, and specificity of 0.94545. The most significant prognostic factors included proportion of positive biopsy specimens, Gleason score (International Society of Urological Pathology (ISUP) grade estimated at routine pathomorphological examination), and presence and length of positive resection margin.Conclusion. Our mathematical model and the nomogram based on it are highly accurate for predicting local recurrence and can therefore be used for choosing an optimal management strategy.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116959418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-09DOI: 10.17650/1726-9776-2022-18-3-76-84
A. Kneev, M. Shkolnik, O. Bogomolov, N. D. Verdiev, G. Zharinov
{"title":"Prostate-specific antigen density as a predictor of recurrence-free survival following combined hormonal-radiation therapy of localized prostate cancer","authors":"A. Kneev, M. Shkolnik, O. Bogomolov, N. D. Verdiev, G. Zharinov","doi":"10.17650/1726-9776-2022-18-3-76-84","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-76-84","url":null,"abstract":"Background. Prostate cancer is amongst one of the most prevalent cancers in men worldwide. Combined hormonal-radiation therapy has become a standard of care for localized prostate cancer definitive treatment. As many as 30 % of men are at risk for disease progression within 10 years following radical treatment.Aim. To assess the significance of prostate-specific antigen (PSA) density as a predictor of recurrence-free survival following combined hormonal-radiation therapy in patients with localized prostate cancer.Materials and methods. We conducted a retrospective study of 272 patients with clinically localized prostate cancer treatment results who received combined hormonal-radiation therapy between January 1996 and December 2016.Results. On the basis of our study, we confirmed high prognostic value of PSA density among patients with localized prostate cancer who received combined hormonal-radiation treatment. We utilized ROC-analysis in order to determine the threshold value of the PSA density index – 0.376 ng/ml/cm3, exceeding of which was associated with statistically significant reduction in the recurrence-free survival rate. The area under the curve was 0.711 (95 % confidence interval 0.653–0.764; p <0.0001). The risk of recurrence increased with rising of PSA density.Conclusion. PSA density has proven to be a reliable tool for assessing the risk of prostate cancer recurrence among patients with localized prostate cancer who have undergone combined hormonal-radiation therapy.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"438 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132073763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer UrologyPub Date : 2022-12-09DOI: 10.17650/1726-9776-2022-18-3-60-66
O. Mailyan, A. Kalpinskiy, I. Reshetov, Yu. V. Anzhiganova, K. Nyushko, А. Kaprin, M. Golovashchenko, S. P. Kokin, V. A. Stakanov, B. Alekseev
{"title":"Prevalence of mutations in DNA repair genes in Russian patients with metastatic castration-resistant prostate cancer","authors":"O. Mailyan, A. Kalpinskiy, I. Reshetov, Yu. V. Anzhiganova, K. Nyushko, А. Kaprin, M. Golovashchenko, S. P. Kokin, V. A. Stakanov, B. Alekseev","doi":"10.17650/1726-9776-2022-18-3-60-66","DOIUrl":"https://doi.org/10.17650/1726-9776-2022-18-3-60-66","url":null,"abstract":"Background. Prostate cancer is one of the most common malignant tumors in men. Tailored treatment approaches to metastatic castration-resistant prostate cancer based on identification of specific biomarkers have been introduced only recently. So far, the Food and Drug Administration has approved two drugs (olaparib and rucaparib) targeting the DNA repair genes.Aim. To assess the frequency of mutations in the DNA repair genes in the Russian population.Materials and methods. The article uses data from two centers (National Medical Research Radiological Center and A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncological Dispensary) which included the largest numbers of patients in the largest Russian multicenter prospective trial ADAM. We performed genotyping of all valid tumor samples from 113 patients with metastatic castration-resistant prostate cancer to identify clinically significant mutations in the DNA repair genes.Results. Next-generation sequencing demonstrated that 27 patients (23.9 %) had clinically significant mutations in DNA repair genes were, including ATM in 6 (5.3 %), BRCA1 in 5 (4.4 %), BRCA2 in 4 (3.5 %), CDK12 in 3 (2.6 %), CHEK2 in 2 (1.8 %), PALB2 in 2 (1.8 %), BRIP1 in 2 (1.8 %), BARD1 in 1 (0.9 %), RAD51B in 1 (0.9 %), and RAD51C in 1 patient (0.9 %).Conclusion. Identification of mutations in the DNA repair genes should become a routine procedure, since a new treatment approach to metastatic castration-resistant prostate cancer is now being introduced.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"145 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114798281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}